Wegovy 1.7mg Reviews: What Does This Dose Actually Feel Like?

What do people actually say about 1.7mg Wegovy?

The accounts that come up most often describe a clear shift in hunger. Where 0.5mg or 1mg felt subtle for many (background-noise reduction rather than a sharp change) 1.7mg is the point where people tend to report leaving food on the plate without thinking about it, or realising mid-afternoon that they forgot lunch. This matches what the pharmacology would predict: semaglutide's GLP-1 receptor activity has been building over each four-week step, and 1.7mg represents a meaningful increase from the 1mg dose.

Side effect reports at this dose are consistent with the rest of the schedule. Nausea is still the most frequently mentioned issue, usually concentrated in the 24 to 48 hours after the injection rather than persisting all week. Constipation, tiredness and occasional headache also feature. A practical note that comes up in patient discussions: the weekly injection day is worth building around something low-key, since energy can dip the following morning. Many people keep their pen in the fridge door so the routine stays consistent, a small thing, but easy habits matter over a titration schedule that runs for months.

The honestly useful context here is that 1.7mg is not where most people stay. For the majority following the licensed schedule, it is a four-week bridge toward 2.4mg maintenance. The weight-loss response at 1.7mg is real, but the experience at 2.4mg is typically what patients describe as the dose where results consolidate.

Is 1.7mg the right stopping point, or just a step?

This question comes up a lot, and it is worth being direct: the Wegovy titration schedule exists primarily to manage tolerability, not to find each person's optimum dose along the way. The full dose schedule runs 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg, and the destination, for most people, is 2.4mg. NICE's appraisal of semaglutide for weight management (TA875, published March 2023) is based on data from the 2.4mg maintenance dose, and recommends reviewing continuation if less than 5% weight loss has occurred after six months on maintenance. 1.7mg sits outside that endpoint.

That said, some people stay at 1.7mg for longer than the standard four weeks, either because they are still managing GI side effects or because their prescriber judges it appropriate. This is a clinical decision, not one to make based on online reviews. The question of whether a lower dose is sufficient is one our prescribers field regularly, and the answer varies by individual, not by what worked for someone else on a forum.

Reviews should also be read with one caveat in mind: people who post about their experience are not a representative sample. Those with strong effects (positive or negative) are more likely to write about it. The clinical trial data from the STEP 1 study, published in the New England Journal of Medicine, remains the most reliable picture of what semaglutide produces across a large, controlled population.

What about side effects specifically at this dose, are they worse than at 1mg?

For some people, yes. Each upward step in the Wegovy schedule can bring a temporary resurgence of the GI effects that were manageable on the previous dose. Nausea, loose stools, indigestion and burping are the most common. The NHS patient information for semaglutide notes that these effects are typically most pronounced when starting or increasing the dose, and that they usually settle within days to two weeks.

Dehydration from repeated nausea or vomiting is something to take seriously, if GI symptoms are severe or persistent, that is a reason to contact your prescriber rather than wait it out. Pancreatitis is a rare but recognised risk with GLP-1 medicines: seek urgent medical attention for severe stomach pain that reaches the back, with or without vomiting. You can report any suspected side effects to the MHRA via the Yellow Card scheme.

What the reviews tend to underplay is how much eating habits influence tolerability. Smaller portions, slower eating and keeping well hydrated all reduce the likelihood of nausea compounding. These are not optional lifestyle tips at this stage, they are part of how the medicine works best. If you are considering Wegovy and weighing up what the titration involves, the full Wegovy overview covers what to expect across the whole course.

How does 1.7mg compare to the highest doses now available?

The Wegovy schedule has expanded since the medicine launched. A 7.2mg dose was approved by the MHRA in January 2026, with a dedicated single-dose pen approved in April 2026, which puts 1.7mg firmly in the early-middle of the range now available, rather than near the top. Trials of the 7.2mg dose reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide significantly. If you want to understand how the doses compare across the full approved range, the page on the highest Wegovy doses covers what is now licensed.

For those still at 1.7mg, that context is not a reason to rush. Dose changes require clinical assessment, evidence of weight loss response, tolerance and current health status. A frank conversation with your prescriber, rather than reading reviews of doses you have not yet reached, is the most useful next step. If you are exploring private treatment and want to understand what a clinical review involves, our treatment page sets out what the consultation covers.

Cost is a practical consideration too, and one that catches people off guard when they first start researching. The Wegovy price comparison page explains what private treatment typically costs in the UK and what to check when comparing providers.